Skip to main content
. 2016 May 18;11(5):e0155806. doi: 10.1371/journal.pone.0155806

Fig 6. In vivo pharmacodynamics of innovator (Wyeth) and generic (Farmalogica) TZP against E. coli 35218Δbla.

Fig 6

Therapeutic equivalence of generic TZP (Farmalogica) with the innovator (Wyeth) against E. coli 35218Δbla, a strain without β-lactamase (plasmid cured). After treatment of mice infected with the cured strain, TZP Farmalogica had a valid nonlinear regression fulfilling all the assumptions with highly significant PD parameters. Both products were described by a single curve, indicating that the generic is therapeutically equivalent to the innovator. As the strain has no β-lactamase, the effect is solely from the piperacillin component of TZP and indicates that the nonequivalence found against E. coli ATCC 35218 is due to tazobactam.